Trial Profile
Phase IIb dose-ranging study of GRC 17536 in patients with neuropathic pain
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2019
Price :
$35
*
At a glance
- Drugs ISC 17536 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 12 Nov 2019 According to an Ichnos Sciences media release, this study is expected to start in 2020.
- 02 Oct 2014 New trial record
- 17 Sep 2014 Glenmark plans to file for this study at the end of the 2014 financial year, according to a media release.